Pathfinder Cell Therapy, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PFND research report →
Companywww.pathfindercelltherapy.com
Pathfinder Cell Therapy, Inc. , a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology.
- CEO
- Richard L. Franklin
- IPO
- 2000
- Employees
- 1
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $66.72K
- P/E
- -0.04
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -4.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 31.81%
- ROIC
- 116.56%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-1,669,000 · 7.84%
- EPS
- $-0.00 · 7.41%
- Op Income
- $-1,119,000
- FCF YoY
- 39.85%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -24.33
- Avg Volume
- 320
Get TickerSpark's AI analysis on PFND
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PFND Coverage
We haven't published any research on PFND yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PFND Report →